Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

Phase 2

Completed

Conditions: Pheochromocytoma
Paraganglioma

Interventions: Drug: Sunitinib

Registration Number: NCT00843037

Lead Sponsor: University Health Network, Toronto

Brief Summary: This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer. Paragangliomas (PGs) are tumours that arise from the para-sympathetic system in the head and neck and sympathetic system in the thorax and abdomen. Paragangliomas that secrete hormones (catecholamines) from the adrenal glands are called pheochromocytomas (PCs). In this study, patients whose disease has advanced or spread despite prior standard therapy, will receive sunitinib for 4-weeks followed by a 2-week rest period, for up to 12 months, in the absence of disease progression. Sunitinib is an investigational drug, which has been shown to shrink tumours in several tumour models. The study will evaluate the efficacy as well as the toxicity profile of sunitinib when used as an alternative treatment for patients with PG/PC tumours.

Detailed Description: This study will be a single arm, open-label, phase II trial of sunitinib in patients with metastatic or locally advanced malignant paraganglioma or phaeochromocytoma. Oral sunitinib (50 mg) will be administered to all patients daily for the first four weeks of a six week study cycle, followed by a 2-week rest. Patients will be assessed for response to study treatment using MRI/CT scans as well as bio-chemical tests, and will receive the study treatment for up to 12 months or until disease progression.

Primary study outcomes include:

To assess the efficacy (response rate) of sunitinib given orally daily for 4 out of every 6 weeks in patients with advanced or metastatic paraganglioma/ pheochromocytoma.

To assess the toxicity of sunitinib in patients with advanced or metastatic paraganglioma/ pheochromocytoma.

To document effects of sunitinib on markers of biochemical activity of advanced or metastatic paraganglioma/ pheochromocytoma.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 25

Inclusion Criteria

Histologically or cytologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability.
Evidence of recent disease progression (radiological, biochemical, symptomatic).
Measurable disease defined as that which can be measured in at least one dimension with a minimum size of 10 mm by CT scan.
ECOG 0-2.
Life expectancy of greater than 24 weeks.
Age > 18 years.
Patients must have normal organ and marrow function.
Patients must have PT/INR/PTT within 1.2 X the upper limit
Patients may have had prior radiation therapy. A minimum of 28 days must have elapsed between the end of radiotherapy and registration onto the study.
Previous Surgery: Previous major surgery is permitted provided that it has been at least 28 days prior to patient registration
Laboratory Requirements Parameter Limit granulocytes (AGC) > 1.5 x 109/L platelets > 100 x 109/L bilirubin < 1.5XULN AST and ALT < 2.5 x ULN Amylase <1.5XULN Lipase <1.5XULN Calcium < 3 mmol/L creatinine < 2.0XULN

Exclusion Criteria

History of other malignancies.
Patients with known brain metastases.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib.
Patients receiving concurrent treatment with other anti-cancer therapy given for paraganglioma or pheochromocytoma or other therapy or other investigational anticancer agents.
Patients who have received prior treatment with any other antiangiogenic agent or multi-targeted tyrosine kinase inhibitors are ineligible.
Patients with any of the following cardiovascular findings are to be excluded:
QTc prolongation or other significant ECG abnormalities.
Current or history of Class III or IV heart failure as defined by the NYHA functional classification system
Patients with prior anthracycline exposure, previous central thoracic radiation that included heart in radiation port, or a history of NYHA Class II cardiac function.
Poorly controlled hypertension
Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry
History of venous thrombosis or pulmonary embolism in the past 3 months
History of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry
Patients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin
Patients with bowel obstruction or any condition that impairs their ability to swallow and retain sunitinib tablets.
Use of agents with proarrhythmic potential is not permitted during the study.
Must be able to stop prohibited selected CYP3A4 inhibitors/inducers prior to starting sunitinib
Patients with pre-existing hypothyroidism prior to enrolment are ineligible unless they are euthyroid on medication.
Pregnant or lactating women, positive pregnancy test, women of childbearing potential who do not agree to use adequate contraception prior to study entry and for the duration of study participation.
Known HIV-positive patients on combination antiretroviral therapy
Greater than +1 proteinuria on urinary dipstick if also >1g urinary protein/24hrs

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open label - Sunitinib	Sunitinib	Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break

Primary Outcome Measures

Name	Time	Method
Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.	Every 12 weeks (2 cycles) up to disease progression or study discontinuation (an average of 13.5 6-week cycles or about 1.5 years).	The primary endpoint of this study was disease control rate (DCR) defined as a partial response (PR), complete response (CR), or stable disease maintained for ≥12 weeks from the initiation of treatment. Tumour response to sunitinib was assessed as per RECIST 1.1 using CT-imaging. Clinically apparent lesions needed to be \>10mm by calliper measurement to be included as targets. The primary endpoint was met despite closing to accrual early.

Secondary Outcome Measures

Name	Time	Method
Biochemical Response (BCR) of > 20% Drop in 24-hour Urinary Metanephrines, Catecholamines or Serum Chromogranin A, Sustained for > 12-week Period	Within 7 days of study registration and every 12 weeks (2 cycles) up to treatment discontinuation (an average of 13.5 6-week cycles or about 1.5 years).	Biochemical and symptom changes: timed urinary catecholamine collection over 24 h included measurements of norepinephrine, epinephrine, dopamine and total metanephrines.
Overall Survival	From time of enrollment until loss to follow-up or death (approximately 125 months for longest patient on treatment).	The median overall survival
Time to Progression	Every 12 weeks (2 cycles) up to disease progression or study discontinuation (an average of 13.5 6-week cycles or about 1.5 years).	Median Progression-Free Survival (PFS)
Overall Response Rate (PR) + (CR)	Every 12 weeks (2 cycles) up to disease progression or study discontinuation (an average of 13.5 6-week cycles or about 1.5 years).	Overall response rate (PR) + (CR) of participants

Trial Locations

Locations (4): University Medical Centre Groningen
🇳🇱
Groningen, Netherlands
University Health Network, Princess Margaret Cancer Centre
🇨🇦
Toronto, Ontario, Canada
Tom Baker Cancer Centre
🇨🇦
Calgary, Alberta, Canada
Hôpital Notre-Dame du CHUM
🇨🇦
Montreal, Quebec, Canada